Open AccessDrug updates and approvals
Author(s) -
Lauren Crump,
Miranda Benfield,
Caleb Ramey,
Ashley Arcara,
Sebin Yang,
Jennifer Brown,
Geoffrey Mospan,
Cortney M. Mospan
Publication year - 2019
Publication title -
the nurse practitioner/the nurse practitioner
Language(s) - English
Resource type - Journals
eISSN - 1538-8662
pISSN - 0361-1817
DOI - 10.1097/01.npr.0000605508.04187.b2
Subject(s) - dolutegravir , medicine , formoterol , drug , tazarotene , drug approval , pharmacology , virology , human immunodeficiency virus (hiv) , dermatology , antiretroviral therapy , asthma , budesonide , viral load , psoriasis
In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir Pressair); and siponimod (Mayzent).